SPLENDRIS
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

SPLENDRIS Trademark

Serial Number: 79136686 • Registration: 4642937

SPLENDRIS is a trademark filed by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. on May 7, 2013. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (10 trademarks)

37F, Main Tower, Lvjing Plaza,
Futian Dist. Shenzhen 518040 , CN

Entity Type: 99

Trademark Details

Filing Date

May 7, 2013

Registration Date

November 25, 2014

Published for Opposition

September 9, 2014

Cancellation Date

May 8, 2023

Goods & Services

Pharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chemical preparations for pharmaceutical purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicines for human purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicated troches, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Prepared Chinese medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Biochemical medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Dietetic substances adapted for medical use, namely, beverages or food in the nature of vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, and mineral food-supplements, which are used for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Drugs for medical purposes, namely, medicines for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 26, 2023 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 26, 2023 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jul 11, 2022 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Jun 9, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Jun 8, 2022 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 11, 2022 INTR
CANCELLED SECTION 71
Jun 11, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 25, 2019 REM3
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 9, 2019 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 5, 2019 CRCV
NEW REPRESENTATIVE AT IB RECEIVED
Jul 4, 2019 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Dec 7, 2018 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 8, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 20, 2015 FICS
FINAL DISPOSITION PROCESSED
Apr 20, 2015 FIMP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 12, 2015 TCCA
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 25, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 25, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 9, 2014 NPUB
PUBLISHED FOR OPPOSITION
Sep 9, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2014 NONP
NEW REPRESENTATIVE AT IB RECEIVED
Aug 7, 2014 NREP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 5, 2014 PREV
ASSIGNED TO LIE
Aug 5, 2014 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 27, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 27, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 27, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 27, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 27, 2014 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2014 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 11, 2014 ERFR
FINAL REFUSAL MAILED
Dec 17, 2013 CNFR
FINAL REFUSAL WRITTEN
Dec 16, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 20, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 20, 2013 TROA
REFUSAL PROCESSED BY IB
Nov 14, 2013 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 23, 2013 RFCS
REFUSAL PROCESSED BY MPU
Oct 22, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 21, 2013 RFCR
NON-FINAL ACTION WRITTEN
Oct 20, 2013 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 16, 2013 MAFR
ASSIGNED TO EXAMINER
Oct 13, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 12, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 10, 2013 REPR